Arrowhead Pharmaceuticals, Inc. (ARWR) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Pasadena, CA, United States. वर्तमान CEO हैं Christopher R. Anzalone.
ARWR के पास है IPO तिथि 1993-12-16, 609 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $9.34B.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Pasadena, California, that develops RNA interference (RNAi) therapeutics for the treatment of intractable diseases. The company maintains a diverse clinical pipeline targeting liver diseases, metabolic disorders, cardiovascular conditions, respiratory diseases, and rare genetic disorders, with candidates in Phase 1 through Phase 3 clinical development. Key programs include ARO-AAT for alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, ARO-HIF2 for renal cell carcinoma, and JNJ-3989 for chronic hepatitis B, developed under collaboration with Janssen Pharmaceuticals. Through strategic partnerships with leading pharmaceutical companies including Janssen and Takeda, Arrowhead leverages its RNAi platform technology to address genetically validated disease targets across multiple therapeutic areas.
